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Abstract
In recent years, marine algae have emerged as a rich and promising source of molecules with potent activities against
various human pathogens. The widely distributed brown alga Lobophora variegata that is often associated with tropical
coral reefs exerts strong antibacterial and antiprotozoal effects, but so far has not been associated with specific anti-viral
activities. This study investigated potential HIV-1 inhibitory activity of L. variegata collected from different geographical
regions, using a cell-based full replication HIV-1 reporter assay. Aqueous L. variegata extracts showed strong inhibitory
effects on several HIV-1 strains, including drug-resistant and primary HIV-1 isolates, and protected even primary cells (PBMC)
from HIV-1-infection. Anti-viral potency was related to ecological factors and showed clear differences depending on light
exposition or epiphyte growth. Assays addressing early events of the HIV-1 replication cycle indicated that L. variegata
extracts inhibited entry of HIV-1 into cells at a pre-fusion step possibly by impeding mobility of virus particles. Further
characterization of the aqueous extract demonstrated that even high doses had only moderate effects on viability of
cultured and primary cells (PBMCs). Imaging-based techniques revealed extract effects on the plasma membrane and actin
filaments as well as induction of apoptosis at concentrations exceeding EC50 of anti-HIV-1 activity by more than 400 fold. In
summary, we show for the first time that L. variegata extracts inhibit HIV-1 entry, thereby suggesting this alga as promising
source for the development of novel HIV-1 inhibitors.
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Introduction
Despite the implementation of the highly active anti-retroviral
therapy (HAART) in 1996, infections with the human immuno-
deficiency virus 1 (HIV-1) still represent a global threat with more
than 34 million infected individuals worldwide and 2.5 million new
infections in 2011 (UNAIDS report on the global AIDS epidemic,
2012). Current treatment of HIV-1 infections still has several
shortcomings with the emergence of resistant viruses, severe side
effects, and high costs being the most pressing issues. Thus, there is
an urgent need for novel anti-retroviral therapeutics. In recent
years, marine algae have emerged as a rich source of bioactive
molecules and have yielded several compounds with remarkable
anti-HIV activity, e.g. lectins which inhibit HIV-1 entry and are
potential HIV-1 microbicide candidates (reviewed in Huskens and
Schols [1]). One of these, Griffithsin (GRFT), was isolated from
the marine red alga Griffithsia sp., [2] and shows high inhibitory
efficacy and safety [3].
Marine brown algal species have also been reported to produce
molecules with promising anti-retroviral properties. Among these,
sulfated polysaccharides, polyphenols and diterpenes are active
constituents [4–6]. Examples include Reverse Transcriptase (RT)-
inhibiting diterpenes from Dictyota pfaffii and sulfated polysac-
charides (fucoidans) from Adenocystis utricularis, which interfere
with early events of HIV-1 replication [7,8]. Interestingly, as
marine macroalgae are consumed by humans on a regular basis in
large parts of Eastern Asia, the relatively low rates of HIV infected
individuals in these areas may be correlated with the consumption
of algae [9]. In fact, a recent proof-of-concept clinical study with
two dietary algae indicated improvement of clinical outcomes of
HIV-1 infection in terms of CD4 cell count and HIV-1 viral load
[10].
Lobophora variegata is a common brown alga that is widely
distributed in shallow water ecosystems of tropical and subtropical
areas, including coral reefs of the Caribbean, the Indian Ocean,
and the Red Sea [11,12]. In coral reefs, L. variegata can be an
abundant part of the ecosystem and exhibits strong allelochemical
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Figure 1. Dose-dependent inhibition of HIV-1 replication and vitality of reporter cells. A: Dose-dependent inhibition of HIV-1 (strain HIV-
LAI) replication in LC5-RIC reporter cells by aqueous extracts from specimens collected at various geographical locations including the Caribbean
(Turneffe Reef, Belize), northern Red Sea (Sinai, Egypt, Canyon Reef) and the central Red Sea (Rose Reef, Kingdom of Saudi Arabia). Cells were treated
with serial dilutions of the aqueous L. variegata extract (ranging from 3.2 up to 100 mg/ml) in triplicates and exposed to the HIV-1 LAI strain. B: Effects
of different concentrations of L. variegata extract (collected from Turneffe Reef, Belize) on viability of indicator cells were measured by the
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defense against potentially deleterious microorganisms [13]. It is
able to induce bacterial assemblage shifts as well as sub-lethal
effects on reef corals [13,14]. Kubanek et al. (2003) isolated a
cyclic lactone, lobophorilide, showing strong activity against
pathogenic and saprophytic marine fungi. Moreover, several
studies demonstrated inhibiting effects of chemical constituents of
L. variegata on several protozoans as well as anti-inflammatory
and other health-promoting effects [5,15–20]. L. variegata also
contains high concentrations of phenolic compounds, mainly
bromophenols [4]. Although L. variegata is a common and well-
studied organism, no specific antiviral effects have been described
to date.
The high antibacterial and antiprotist potential of L. variegata,
led us to investigate whether this organism also displays antiviral
activity. Accordingly, we evaluated the capacity of extracts
produced from L. variegata, specimens collected from coral reefs
in different geographical regions (Caribbean and Red Sea) to
inhibit HIV-1 infection, using various virus strains. In addition, we
used live cell-based and microscopic imaging approaches to
characterize mechanisms of activity and potential side effects of
algal extracts from L. variegata.
Materials and Methods
Ethics statement
The study site of Rose Reef (Saudi Arabia) does not fall under
any legislative protection or special designation as a marine/
environmental protected area. No special permit is required for
the inshore coastal, reef, and intertidal areas around Thuwal. The
Saudi Coast Guard Authority under the auspices of KAUST
University issued sailing permits to the site, which included sample
(algae) collection. All necessary permits for the collections at
Turneffe Reef (Belize) were obtained for the described study by
ALDEBARAN Marine Research&Broadcast (Hamburg, Ger-
many) which complied with all relevant regulations.
Sample collection and extraction
Thalli of Lobophora variegata were collected by SCUBA diving
at several locations. Caribbean samples were collected on a sailing
trip to Belize with the German small-size research vessel
‘‘Aldebaran’’ in March 2009 at Turneffe reef (17u 16.709 N, 87u
48.399 W). Specimens from Northern Red Sea coral reefs were
collected on a field trip to Dahab (Sinai, Egypt) in November 2009
at Canyon reef (28u 33.299 N, 34u 31.2479 E). Samples from
Central Red Sea coral reefs were collected at Rose Reef, Saudi
Arabia (22u 22.509 N, 38u 53.839 E) in April 2012. Directly after
collection, any visible contaminations were removed from algal
thalli, samples were air dried for 8 to 12 h and stored at 220uC.
Prior to extraction, the algal material was ground into a fine
powder using liquid nitrogen. Aqueous and methanolic extracts
were prepared by addition of 1 ml distilled water or methanol to
100 mg of powdered algal material. Samples were briefly vortexed
and extracted at 4uC overnight. Subsequently, samples were
centrifuged at 13,000 g for 30 min to remove particulate material
and then stored at 220uC until further use. Unless otherwise
stated, the aqueous extract prepared from full-sunlight exposed
thalli of L. variegata was used for all experiments.
In order to analyze the solubility of potentially active
compounds of the aqueous L. variegata extract in organic
solvents, liquid/liquid extraction was performed. Briefly, 3 ml of
extract were mixed with 3 ml of hexane or chloroform, shaken for
2 min and centrifuged at 13,000 g for 20 min for efficient phase
separation. The resulting solvent phases were dried in the rotation
evaporator and re-suspended in ultrapure water (Chromasolv,
Sigma Aldrich, Taufkirchen, Germany).
Cell culture
HeLa cells, HEK 293T cells, and the HIV-1 indicator cell lines
(LC5-RIC and LC5-RIC-R5) were kept under standard condi-
tions at 37uC in 5% CO2 in Dulbecco’s modified Eagle medium
(DMEM containing GlutaMAX-1; Gibco, Darmstadt, Germany)
or very-low-endotoxin(VLE)-RPMI 1640 medium (Biochrom AG,
Berlin, Germany) supplemented with 10% fetal bovine serum
(Biochrom AG) and 1% antibiotic-antimycotic solution (Gibco). In
order to maintain stable reporter and CD4 receptor expression of
LC5-RIC/LC5-RIC-R5 reporter cells, 0.74 mg ml21 Geneticin
(G418 sulfate; PAA Laboratories, Pasching, Austria) and
0.13 mg ml21 hygromycin B (PAA Laboratories) were added to
the cell culture medium at every second passage.
Virus stock preparation
Virus stocks were produced in HEK 293T cells by transfection
with the following infectious molecular clones: pLAI.2, pNL(AD8)
(HIV-1 AD8 Macrophage-Tropic R5), HIV-1 p7324-1 (multidrug
resistant molecular clone with patient-derived mutations in
Reverse Transcriptase encoding sequences) and pBR-NL4-3
V92th014.12-IRES-eGFP (HIV-1 NL4-3 Gag-iGFP-reporter vi-
rus,[21]) Briefly, HEK 293T cells were seeded in 6-well plates and
transfected with 1 mg of the corresponding plasmid DNA per well
using 3.8 ml of FuGene HD transfection reagent (Roche),
following the manufacturer’s instructions. After 72 h, the super-
natant was harvested, centrifuged for 5 min at 2,000 g, aliquoted,
and frozen at 280uC. Pseudo-typed viruses harboring the
glycoprotein of the Vesicular Stomatitis Virus (VSVg) were
prepared by co-transfection of HEK 293T cells with 0.5 mg of
the HIV-1 env-defective molecular clone pNL4–3Denv and 0.5 mg
of pMD2.G (Addgene, MA) for expression of VSV-G. The HIV-1
strain HIV-1 KIII was prepared from supernatants of the HIV-
1IIIB producer cell line KE37.1-IIIB. Briefly, KE37.1-IIIB cells
were adjusted to 86105 per ml and cultured for 48 h. Virus-
containing culture supernatants were harvested by centrifugation
at 2,000 g, passed through a 0.45 mm pore-sized filter (Sartorius,
Goettingen, Germany), aliquoted and frozen at 280uC. The
primary HIV-1 isolate HIV-1 PAT891 was isolated from
cerebrospinal fluid (CSF) of an HIV-1 infected individual as
described elsewhere [22]. Virus preparations were quantified by
determining p24 levels (Gag-p24 enzyme-linked immunosorbent
assay; Applied Biosystems, Carlsbad, CA), according to the
manufacturer’s instructions. In addition, viral preparations were
tested on LC5-RIC cells in order to determine levels of infectious
viruses. The volumes of virus stocks that were used for infection of
LC5-RIC cells were determined according to the following critera:
(i) more than 100-fold increase of the relative fluorescent signal by
HIV-1 infection, (ii) relative signal induction levels below the
plateau, and (iii) a reduction of the relative MTT signal by less
than 10%. [22].
colorimetric MTT assay. LC5-RIC reporter cells were treated with serial dilutions (ranging from 3.1 up to 400 mg/ml) of the aqueous L. variegata extract
for 48 hours. Data are given relative to untreated cells (100%).
doi:10.1371/journal.pone.0103895.g001
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Standard assay setup for testing of HIV-1 inhibitory
activities
A description of the full assay procedure can be found elsewhere
[22]. Briefly, LC5-RIC cells were seeded into 96-well plates
(mCLEAR-Plate Black; Greiner Bio-One, Kremsmuenster, Ger-
many) at a density of 104 per well at 24 h prior to infection. L.
variegata aqueous extracts were tested in serial dilutions in
triplicates. Stock solutions of aequous L. variegata extracts,
reference compounds and virus preparations were diluted with
cell culture medium. For treatment and infection, 100 ml of
compound solution and 20 ml of diluted virus inoculum were
added to each test well, with each extract concentration tested in
triplicate wells. Plates were incubated for 48 h after virus addition
under standard conditions at 37uC in 5% CO and subsequently
tested for fluorescent reporter signal intensity with a fluorescence
microplate reader (Tecan infinite M200 (Tecan, Crailsheim,
Germany)) at wavelengths 552 nm for excitation and 596 for
emission. The influence of the extracts on the viability of LC5-RIC
cells was determined by a standard MTT test [23] directly after
reporter signal measurement. Cell cultures were incubated with
50 mg of MTT solution (Sigma-Aldrich, Taufkirchen, Germany)
in 100 ml of culture medium for 2 h under standard culture
conditions. After removal of MTT solution, cells were lysed by
addition of 100 ml of lysis solution (10.0% [wt/vol] SDS and 0.6%
[vol/vol] acetic acid in dimethylsulfoxide [DMSO]). MTT
formazan concentrations were determined by an ELISA plate
reader (Tecan Infinite M200) at a test wavelength of 570 nm and a
reference wavelength of 630 nm. Values for treated HIV-1-
infected cultures were related to those of untreated, HIV-1-
infected, cultures in the same plate.
RNA and DNA quantification
For the quantification of viral RNA and DNA in infected LC5-
CD4 cells, cells were seeded in 12-well plates. 24 hours later
medium was replaced and cells were treated with either 65 mg/ml
L. variegata aqueous extract or PBS and exposed to HIV-1LAI.
For the RNA-quantification, 200 nM Efavirenz was added to each
sample to inhibit RNA-turnover by HIV-1 reverse transcriptase.
Samples for RNA and DNA quantification were collected 4 or 24
hours p.i., respectively. After washing of cells with PBS before
(three times) and after (twice) trypsination, RNA and DNA were
isolated using the RNeasy kit or the DNA Mini (QIAGEN)
according to the manufacturer’s manuals. RNA and DNA
quantification was performed as described in Helfer et al. (2014)
[24]. Briefly, RNA levels were quantified by relative qPCR with
specific primers for HIV-1 and calculation was performed with the
222DDCT method. Expression of RNA-Polymerase II was used as
reference. For determination of HIV-1 DNA loads, an absolute
quantification was done by qPCR using the TH4-7-5 cell line as
external standard. b-globin was used as reference gene (Kabamba-
Mukadi et al., 2005) [25].
PBMC Assay
Peripheral blood mononuclear cells (PBMCs) were prepared
from whole blood of healthy donors (obtained from the blood bank
of the German Red Cross, Munich, Germany) according to a
standard protocol (Current protocols in immunology; 7.1.1–7.1.8
April 2009, Supplement 85). 72 h prior to infection, PBMC (pools
of cells from 4 donors) were stimulated by the addition of
Interleukin-2 (50 units per ml of cell culture medium; Sigma-
Aldrich, Taufkirchen, Germany). For infection experiments,
56105 cells per well were seeded into 96-well plates. Treatment
and infection of PBMC was carried out according to the standard
assay setup as described above by using the HIV-1 LAI strain for
infection. Four days after infection, 20 ml of supernatant from each
well was transferred to LC5-RIC indicator cells in order to assay
the production of infectious HIV-1 progeny from treated or
untreated PBMC. The reporter signal intensity of the LC5-RIC
indicator cells was measured at 48 h after addition of PBMC
supernatants. Vitality of PBMCs was determined by an MTT test
as described for LC5-RIC cells.
High Content Analysis
HeLa cells were transferred into 96-well plates, treated with
different concentrations of L. variegata-extract for 24 h, then fixed
and nuclei stained with Hoechst 33342 and b-tubulin stained with
b-tubulin Alexa Fluor 488 (Life Technologies, Darmstadt,
Germany). Images were acquired with a ZEISS Cell Observer
(Carl Zeiss, Jena, Germany) system and a 10x Plan-NEOfluar
objective with filters sets No. 49 (360/40; FT 400; BP 460/50 and
38 (475/40; FT 500; BP 530/50). Images were analyzed using the
Physiology Analyst of the ASSAYbuilder module of AxioVision
4.6. Following the manufacturers protocol, nuclei were used to
automatically detect cells. A ring mask around the nucleus was
generated and used to detect b-tubulin fluorescence. The cell
numbers and the nucleus shape of individual cells was determined
for at least 4 randomly selected fields of view per well. The number
of untreated control cells was set to 100%, and a treatment-caused
alteration was set in relation to this. The average nuclear form
factor of the control cells was used as a reference for a normal
state. Increased form factor represents a tendency towards
fragmented and irregular nuclei, which is usually an indicator of
apoptosis, whereas a decreased form factor typically results from
rounded up cells, indicating necrosis.
Single Cell Analysis
By controlling locations of adhesive (fibronectin) and non-
adhesive areas (PEG) on a coverslip, micro-patterns are generated
and result in a highly reproducible and polarized cell organization.
Using this technique, many thousands of living cells can be
positioned on a single coverslip chip, and cellular feature analysis
can subsequently be performed with optimal reproducibility and
accuracy. HeLa cells were plated on CYTOO chip (Cytoo,
Grenoble, France) coverslip with Y-shaped fibronectin micro-
patterns. Cells were either left untreated (control) or treated for
24 h with L. variegata aqueous extract at a final concentration of
2000 mg ml21 in culture medium. Subsequently, cells were fixed
and stained for DNA (Hoechst33342), actin (Alexa Fluor 488
Phalloidin, Life Technologies) and membrane (Wheat Germ
AgglutininTexasRed, Life Technologies). Cells were imaged with
a ZEISS Cell Observer System and a 20x Plan-APOchromat
objective with filters sets No. 49 (blue), 38 (green) and 43 (red).
TOA
Time-of-addition (TOA) assays were carried out using a slightly
modified standard assay setup in 96-well plates using 100 ml of
compound solution and 20 ml of diluted virus inoculum. Virus
(HIV-1 LAI) was added to LC5-RIC cultures at time point 0.
Reference inhibitory compounds (Griffithsin (GRFT), T-20, AZT
(Zidovudine) and Efavirenz (EFV), all obtained from the NIH
AIDS Reagent Program) and the aqueous L. variegata extract
were added to the cultures at different time points after addition of
virus preparations to final concentrations of 2x EC50 in each well.
At least 10 different time points were evaluated in triplicates for
each compound. Cultures were incubated for 48 h and subse-
quently analyzed for reporter signal intensity as described above.
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Figure 2. Effects of treatment with different concentrations of L. variegata extracts on multiple cellular parameters. A: Effects of high
extract concentrations on cell loss (left) and nuclear shape of HeLa cells as an indicator of either apoptosis or necrosis (right). B: CYTOO chip single
cell assay for morphometry: microscopic images of HeLa cells spotted on fibronectin Y-patterns either control- (top row) or extract- (bottom row)
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Analysis of HIV-1 attachment
HIV-1 attachment assays were performed with LC5-RIC-R5
cells and HIV-1 NL4-3 Gag-iGFP reporter virus in the presence of
the fusion inhibitor T20 (100 nM) to promote attachment of virus
particles to cells. Cells were plated on 24624 mm cover slips in 6-
well plates. After 24 h, the culture medium was replaced with fresh
medium containing T20 (50 nM) and investigational inhibitors
(i.e. 250 mg ml21 L. variegata extract, or 50 nM Griffithsin) and
virus inoculum (,8 pg p24 per cell). Control samples lacked
investigational inhibitors in the medium and included samples
with virus inoculum ( = virus control) or without virus (background
control). The cells were then incubated at 37uC for 4 hours,
washed once with PBS and treated with 2% PFA containing DAPI
for 20 min at room temperature. The cells were then washed
again with PBS, and cover slips were fixed onto glass slides with
Mowiol (Polysciences, Inc.) overnight at room temperature.
Analysis was carried out by fluorescence microscopy (Nikon TiE
equipped with Perkin Elmer UltraView Vox System). Exposure-
times: GFP: 100 ms, DAPI: various.
Calculation of values and curve fits
Curve fits and EC50 calculations were performed by SigmaPlot,
version 11.0 (Systat Software, Chicago, IL) or Prism, version 4
(GraphPad Software, La Jolla, CA). Statistical analysis of data was
carried out with the GraphPad Prism program. Significances of
differences between data sets were determined by calculating two-
tailed P values using the Mann-Whitney-U test.
Results
Aqueous extracts of Lobophora variegata specimens from
different geographical origins inhibit HIV-1 replication
Several aqueous extracts of Lobophora variegata collected from
various geographical origins were tested in a cell-based full-
replication assay for anti-HIV-1 activity. All aqueous extracts
inhibited HIV-1 replication in a clearly dose-dependent manner.
(Figure 1A). Liquid/liquid extractions of the L. variegata extracts
with organic solvents revealed anti-HIV-1 activity solely in the
aqueous and not in the organic phases, pointing to a highly
hydrophilic nature of the active components (data not shown).
L. variegata aqueous extracts show only minor toxic
effects at even high concentrations
Effects of L. variegata extracts on cells were first assessed by
MTT assay, which measures cellular metabolic activity and is
often used to assay cell viability. Viability of the indicator cells was
not affected by treatment with L. variegata extracts at concentra-
tions up to 400 mg ml21, which exceeded the concentration
required for full HIV-1 inhibition (approx. 50 mg ml21) (Fig-
ure 1B). Even a long-term exposure of Hela cells with a single dose
of 400 mg ml21 for up to seven days did not result in any
detectable toxicity (Fig. S1 in File S1). Toxic effects were also
studied in HeLa cells treated with extract concentrations up to
2 mg ml21 by High Content Analysis of cells with stained nuclei
and microtubuli. Whereas no significant effects on cell cycle state
(ploidity) and b-tubulin were observed (data not shown), mild cell
loss of approximately 20% and a slight induction of apoptosis was
observed in cells treated with the highest extract concentration
(Figure 2A).
Next, effects of the L. variegata aqueous extract were analyzed
on the single cell level. Microscopic images clearly depicted
pronounced changes of several cellular features at higher extract
concentrations, including a reduced membrane signal, re-arrange-
ment of actin filaments, and a less well-defined Y-shaped
morphology (Figure 2B). Automated cell feature extraction by
High Content Analysis revealed a significant increase of cell size
(mean cell area), reduction of mean actin intensity, increase in the
number of actin fiber bundles, and substantially increased number
of membrane aggregates (Figure 2C).
L. variegata aqueous extract is active against a panel of
HIV strains and in primary cells
In order to further characterize the anti-HIV-1 potential of
aqueous L. variegata extracts, we tested a panel of HIV-1 variants
consisting of laboratory strains with different cellular tropisms, a
multi-drug resistant HIV-1 strain with patient-derived reverse
transcriptase mutations, a primary HIV-1 strain derived from the
cerebrospinal fluid of an HIV-1 infected patient (Kremb et al.,
2010) and HIV-1 particles pseudotyped with the G-Protein of the
Vesicular stomatitis virus (Table 1). L. variegata extracts inhibited
infection by the two X4-tropic (lymphotropic) strains, HIV-1LAI
and HIV-1KIII as well as the R5-tropic (macrophage-tropic) strain,
treated (50 mg ml21, nuclei in blue, actin in green, membrane in orange/red). C: Results of automatic feature extraction by High Content Analysis
done with approx. 150 cells per experiment and treatment. Asterisks indicate statistical significance (***p,0,001).
doi:10.1371/journal.pone.0103895.g002
Table 1. Evaluation of anti-HIV-1 activity of aqueous L. variegata extract activity with a panel of HIV-1 strains and LC5-RIC indicator
cells.
Virus strain characteristics EC50 r2
HIV-1 LAI X4 tropic 8.12 1.0000
HIV-1 KIII X4 tropic 3.64 1.0000
HIV-1 AD8 R5 tropic 2.62 0.9980
HIV-1 p7324–1 multi-drug-resistant 7.77 0.9989
HIV-1 PAT891 primary isolate 5.38 0.9982
HIV-1 VSVg pp VSV envelope 4.93 1.0000
The panel includes viruses using the chemokine co-receptor CXCR4 (X4 tropic) or CCR5 (R5 tropic), a multi-drug-resistant HIV-1 variant with patient-derived reverse
transcriptase mutations, a primary HIV-1 isolate isolated from cerebrospinal fluid, as well as HV-1 virus particles bearing the G-protein of the vesicular stomatitis virus in
the envelope. EC50 values (mg aqueous extract per ml cell culture medium) were calculated by SigmaPlot and R-squared parameters are given.
doi:10.1371/journal.pone.0103895.t001
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HIV-1AD8. The corresponding EC50 values ranged from 2.6 to
8.1 mg extract per ml and did not correlate with virus tropism.
Moreover, we found a potent inhibitory activity against the multi-
drug-resistant HIV-1 strain and the primary HIV-1 virus isolate.
Furthermore, L. variegata extracts also inhibited infection by the
VSV-G pseudotyped HIV-1 particles with an EC50 value similar
to those obtained for native HIV-1 strains.
As HeLa cells are not the natural target cells of HIV-1, we
further tested the potency of L. variegata aqueous extract to
protect primary cells from HIV-1 infection. We found that L.
variegata aqueous extract also inhibited HIV-1 replication in
peripheral blood mononuclear cells (Figure 3A) with a moderate
decrease of cell vitality at intermediate extract concentrations
(Figure 3B).
L. variegata aqueous extract inhibits HIV-1 infection at an
early stage of virus replication
Our next aim was to characterize the mode-of-action by which
the L. variegata extract inhibits HIV-1 replication. We first
employed a time-of-addition assay [22] to identify which steps of
the HIV-1 replication cycle are affected by the L. variegata extract
(Figure 4A). This assay revealed that L. variegata extract clearly
inhibits an early step in the HIV-1 replication cycle which is
different from and precedes the steps targeted by the entry
inhibitor Griffithsin, the fusion inhibitor T-20 and the reverse
transcription inhibitor Efavirenz. To evaluate the effect of L.
variegata extract on HIV-1 attachment behavior, GFP-labelled
virus particles were incubated with HIV-1 indicator cells in
medium containing investigational inhibitors (i.e. L. variegata
extract or Griffithsin) and the distribution of HIV-1 particles was
analyzed by spinning-disc confocal microscopy (Figure 4B). All
samples also contained the fusion inhibitor T20 to prevent virus
uptake. Virus particles associated predominantly with host cells in
virus-containing samples lacking investigational inibitors (i.e. virus
control in Figure 4B). Attachment of virus particles was increased
even further by treatment with Griffithsin, which is in agreement
with the reported enhancement of virus binding to the CD4-
receptor by Griffithsin [26]. In contrast, treatment with L.
variegata extract led to more random distribution of virus particles
with occurrence of virus particles in cell-free areas of the slide,
indicating arbitrary attachment of the virus particles to non-
cellular surfaces. These results suggest that L. variegata extracts
may change the attachment behavior of virus particles, possibly
promoting their attachment to unspecific surfaces. Additional
experiments were conducted to validate the inhibition of HIV-1 at
an early stage of the viral replication cycle. Quantification of
intracellular HIV-1 RNA levels in HIV-1 target cells (LC5-CD4)
at 4 hours post infection showed a substantial reduction of viral
RNA levels in cells treated with the L. variegata extract
(Figure 5A). Similarly, quantification of proviral copies revealed
a clearly reduced viral load in extract-treated cells (Figure 5B).
Environmental conditions affect anti-HIV-1 activity of the
L. variegata aqueous extract
To test whether growth conditions of Lobophora affect its HIV-1
inhibitory potency we compared the activities of Lobophora
samples collected from various settings. All samples showed anti-
HIV-1 activity, regardless of their geographical origin (Caribbean
and Red Sea). However, specimens from the same geographical
origins that were exposed to different environmental conditions
showed different potencies of anti-HIV-1 activity. Thus, extracts of
Northern Red Sea specimens collected from a shady location
showed higher anti-HIV-1 activity than extracts of specimens from
a sunny location. (Figure 6A). Furthermore, extracts of Caribbean
specimens that had been overgrown by epiphytes showed higher
anti-HIV-1 activity than extracts of samples free of epiphytes.
(Figure 6B).
Figure 3. Effects of the L. variegata extract on HIV-1 infection of primary cells. A: Dose-dependent inhibition of HIV-1 replication in primary
cells treated with L. variegata aqueous extract. Peripheral blood mononuclear cells (PBMC) were isolated from whole blood and exposed to the
lymphotropic variant HIV1-LAI. Pooled PBMCs were stimulated by treatment with IL-2 for 72 hours, followed by the addition of virus inoculum (HIV-1
LAI) and diluted extracts and continued incubation for 4 days under standard cell culture conditions. The production of infectious HIV-1 progeny was
titrated on LC5-RIC indicator cells. B: Vitality of HIV-1-infected PBMC at corresponding extract concentrations.
doi:10.1371/journal.pone.0103895.g003
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Discussion
In this study, a combination of a cell-based HIV-1 full
replication assay and imaging-based techniques was used to
identify and characterize anti-HIV-1 activities in a crude aqueous
extract of the brown alga Lobophora variegata.
All aqueous extracts of L. variegata showed potent and dose-
dependent inhibition of HIV-1 replication, although the specimens
used in their production originated from different and far apart
geographical locations, (i.e. Atlantic (Caribbean) and Indo-Pacific
(Red Sea). This suggests that all L. variegata specimens are
capable of inhibiting HIV-1 activity by a common principle.
Anti-HIV-1 activity of L. variegata was detected exclusively in
aqueous but not in organic phases of the extract, indicating a
highly polar nature of the active principle. Similarly, other algae-
derived molecules with high anti-retroviral activity, such as
sulfated polysaccharides and the lectin Griffithsin, were also
identified in aqueous extracts [2,6]. In contrast, anti-protozoal
activities of L. variegata occurred exclusively in organic extracts.
This indicates that anti-protozoal and anti-HIV-1 activities are
mediated by different, unrelated components of L. variegata.
Evaluation of cellular toxicity of extracts by MTT assay, which
is an indicator of cell metabolism [27], revealed no toxic effects of
the extract on the HIV-1 indicator cells even at the highest
concentrations. To evaluate effects of L. variegata on other
cellular parameters we used High Content Analysis which allows
simultaneous analysis of multiple cellular parameters. This
technology, revealed no impairment of the cell cycle at any
concentration (data not shown), at any concentration. However,
changes in nuclear shapes associated with apoptosis, increased cell
areas and changes in the actin cytoskeleton were apparent at the
highest extract concentration of 2 mg ml21. Furthermore, treat-
ment with L. variegata extract at this high concentration had a
relatively pronounced effect on the plasma membrane, suggesting
that the L. variegata aqueous extract also contains a membrane-
active constituent. These cellular effects only occur at much higher
Figure 4. Analysis of the mechanism-of-action of the L. variegata extract. A: Time-of-compound addition dependent inhibition of HIV-1
replication. HIV-1 indicator cells were treated with various reference compounds targeting approved steps of HIV-1 replication (GRFT: virus
attachment; T-20: virus/cell fusion; AZT: reverse transcription, competitive; EFV: reverse transcription, non-competitive) and the L. variegata aqueous
extract at concentrations of 26EC50. All LC5-RIC indicator cell cultures were exposed to HIV-1 LAI. at time point 0 with test and reference compounds
were added to the cells at different time points. At least 10 different time points in triplicates were measured for each compound. B: Analysis of HIV-1
attachment using GFP-labeled HIV-1 particles. HIV-1 indicator cells were exposed to the HIV-1 NL4-3 Gag-iGFP reporter virus for 4 hours in the
presence of the fusion inhibitor T20 and test compounds (250 mg/ml aqueous L. variegata extract or 50 nM Griffithsin). Nuclei were stained with DAPI.
doi:10.1371/journal.pone.0103895.g004
Figure 5. L. variegata aqueous extract inhibits HIV entry. A. Reduction of input HIV-1 viral RNA levels by treatment with L. variegata aqueous
extract. LC5-CD4 cells were infected with HIV-1 in the absence or presence of L. variegata aqueous extract. 4 hours p.i. cells were washed extensively
to remove inoculum and subsequently total RNA was isolated. After reverse transcription, qPCR was performed to quantify viral RNA levels. HIV-1
transcript levels were normalized to RPII levels. Means and standard deviations are shown in relation to untreated/uninfected cells in percent. B.
Reduction of HIV-1 DNA loads by treatment with L. variegata aqueous extract. LC5-CD4 cells were infected with HIV-1 in the absence or presence of L.
variegata aqueous extract. 24 hours later, cells were washed extensively to remove inoculum RNA isolated and cDNA produced from RNA. To quantify
viral DNA loads, absolute qPCR was performed. Means and standard deviations are shown in relation to untreated/uninfected samples in percent.
doi:10.1371/journal.pone.0103895.g005
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Figure 6. Effects of different growth conditions of L. variegata on the HIV-1 inhibitory potential. A: Comparison of extract activities of
specimens from the Northern Red Sea, collected from sunny or shady locations. B: Comparison of extract activities of specimens from the Caribbean
with or without overgrowth by epiphytes. Epiphytes were removed before extraction of L. variegata. All extracts were tested on LC5-RIC reporter cells
using the HIV-1 strain HIV-LAI.
doi:10.1371/journal.pone.0103895.g006
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extract concentrations than those required for anti-HIV-1 activity
and can most probably be attributed to other compounds.
However, to further improve the safety of L. variegata extracts
for humans both activities should be separated.
L. variegata extracts inhibited replication of all tested virus
strains including HIV-1 strains with different cellular tropisms, a
multi-drug resistant HIV-1 strain and a primary HIV-1 isolate
obtained from an infected individual. In addition, anti-HIV-1
activity was confirmed with primary human HIV-1 target cells
(PBMC). Together these data support the ability of the L.
variegata aqueous extract to inhibit HIV-1 infection under
physiologically relevant conditions.
To learn more about the mechanism-of-action by which the
extract targets HIV-1 replication, we employed a strategy of time-
dependent addition of the test compound to infected cells. This
method was recently demonstrated to be adaptable to crude
biological extracts [22]. The resulting inhibition curve clearly
points to an interference of the L. variegata aqueous extract with a
very early step of virus replication. A substantial reduction of viral
RNA levels and proviral copies in infected cells treated with the L.
variegata extract further support this hypothesis. We next
analyzed the effect of the extract on the attachment of GFP-
labeled HIV-1 particles to target cells by microscopic imaging.
The observed unspecific immobilization of viral particles on
surfaces including non-cellular parts indicates a direct interaction
of extract compounds with HIV-1 virions. Although viral particles
can be found attached to cells, viral entry is obviously impaired.
This may either be related to a virucidal effect or to an
immobilization of the virus on the cell membrane making it
impossible for the virus to further proceed in its replication cycle.
The pronounced effect of the extract on the plasma membrane at
high extract concentrations, including a reduced membrane signal
and an increase of membrane aggregates, might be related to the
presence of membrane-active compounds. These could interfere
with the viral membrane leading to the observed immobilization
and impaired viral entry into target cells. In addition, the strong
inhibition of virions pseudotyped with a non-HIV-1 glycoprotein
(VSV-g) makes a specific interaction of extract compounds with
the HIV-1 glycoproteins unlikely and argues in favor of the viral
membrane as the target structure. This inhibitory mechanism is
different from the well-characterized HIV-1 entry inhibitors T-20
and Griffithsin or the plant-derived triterpene glycyrrhizin which
may reduce the fluidity of the plasma membrane leading to an
inhibition of virus/cell fusion [28,29]. Thus, the anti-viral effect of
the L. variegata aqueous extract may represent a new inhibitory
principle and should be characterized in more detail.
L. variegata inhabits a wide range of ecological settings and can
have strong allelochemical effects on its environment [13,14]. It is
likely that different growth conditions may have effects on the
chemical composition of the thalli and thus on anti-viral activity.
Our results clearly showed pronounced differences in anti-HIV-1
activities of algae from different environmental settings. Appar-
ently, environmental factors such as light conditions or overgrowth
by epiphytes influence anti-retroviral activities of specimens.
Environmental stress generally leads to the induction of diverse
protective molecules in algae [30]. These include polyphenols,
sulfated polysaccharides, or proteins and are used as sunscreens,
scavengers of reactive oxygen species (ROS), deterrents, or anti-
microbial agents by these organisms [30,31]. Thus, it is possible
that the anti-HIV-1 activity observed in the aqueous extract may
be part of the stress response of this alga.
In summary, our results reveal for the first time a strong and
broad anti-retroviral activity of the common brown macroalga L.
variegata and suggest a direct interaction of extract constituents
with the viral particles. These findings further complete the rich
anti-microbial spectrum of this algal species and suggest its extracts
as a promising source for the development of novel HIV-1
inhibitors.
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